{"nctId":"NCT04540094","briefTitle":"Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital","startDateStruct":{"date":"2021-06-01","type":"ACTUAL"},"conditions":["Sepsis"],"count":300,"armGroups":[{"label":"5% Human Albumin Solution","type":"EXPERIMENTAL","interventionNames":["Drug: Human albumin"]},{"label":"Intravenous balanced crystalloid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Balanced crystalloid solution"]}],"interventions":[{"name":"Human albumin","otherNames":[]},{"name":"Balanced crystalloid solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAdult patients (18 years or older) who present to UK NHS hospitals with community acquired sepsis meeting all of the 4 criteria:\n\n1. Clinically suspected or proven infection resulting in principal reason for acute illness;\n2. NEWS score â‰¥5 (or NEWS2 if adopted in recruitment site);\n3. Hospital presentation within last 12hrs; and\n4. Clinician decision has been made that immediate (within 1 hour) intravenous fluid resuscitation is needed.\n\nExclusion Criteria:\n\n1. \\>1 litre of intravenous crystalloid fluid or any intravenous HAS administered prior to eligibility assessment;\n2. Requirement for immediate surgery (within one hour of eligibility assessment);\n3. Chronic renal replacement therapy;\n4. Known allergy/adverse reaction to HAS;\n5. Balanced crystalloid or HAS not available;\n6. Known adverse reaction to blood products;\n7. Palliation/end of life care (explicit decision by patient/family/carers in conjunction with clinical team that any active treatment beyond symptomatic relief is not appropriate);\n8. Religious beliefs precluding HAS administration;\n9. Previous recruitment in the trial;\n10. Known recent severe traumatic brain injury (within 3 months);\n11. Patients with permanent incapacity;\n12. Known recruitment in another CTIMP studies within the last 30 days where co-enrolment has not been agreed.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Recruitment Rate","description":"We measured the recruitment rate to assess deliverability. We aimed to recruit 300 participants in approximately 1 year in a 1:1 ratio into each treatment arm.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]}]},{"type":"PRIMARY","title":"30-day Mortality","description":"Assessment of how many participants in each arm died after 30 days to determine the effect size between the treatment groups.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Data Completeness of Primary Outcome","description":"Feasibility Outcome assessing the number of participants who provided data for clinical primary outcome (30 day mortality)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Withdrawal From Study","description":"Feasibility Outcomes assessing the number of participants who withdraw from study intervention and/or data collection","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Receive Any Other Fluid Apart From Intervention or Control in First 6 Hrs After Recruitment","description":"Feasibility Outcome- number of patients who receive any other fluid apart from intervention or control in first 6 hrs after recruitment","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Start of In-hospital Intravenous Fluids","description":"Feasibility Outcome- Time to start of in-hospital intravenous fluids","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"In-hospital Mortality","description":"Secondary Clinical Outcome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"90-day Mortality","description":"Secondary Clinical Outcome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume of Randomised Fluid Delivered in Each Arm in the First 6hrs","description":"Secondary Clinical Outcome- Volume of randomised fluid delivered in each arm in the first 6hrs","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"750","spread":null},{"groupId":"OG001","value":"1250","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stay","description":"Secondary Clinical Outcome","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"15.9"},{"groupId":"OG001","value":"13.9","spread":"19.3"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Admitted to Critical Care (HDU/ICU)","description":"Secondary Clinical Outcome- Proportion of patients admitted to critical care (HDU/ICU)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Stay in Critical Care (HDU/ICU)","description":"Secondary Clinical Outcome- Length of stay in critical care (HDU/ICU)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"5.9"},{"groupId":"OG001","value":"1.5","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Needing Intravenous Vasopressors","description":"Secondary Clinical Outcome-number of participants needing intravenous vasopressors","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Needing Renal Replacement","description":"Secondary Clinical Outcome- Number of participants needing renal replacement","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Needing Invasive Ventilation","description":"Secondary Clinical Outcome- Number of participants needing invasive ventilation","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Readmitted in First 90 Days After Discharge","description":"Secondary Clinical Outcome- Number of patients readmitted in first 90 days after discharge","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Developing Acute Kidney Injury (AKI)","description":"AKI Defined using National Institute for Health and Care Excellence (NICE) criteria:\n\nA diagnosis of AKI may be made if there is one of the following:\n\nA rise in serum creatinine of 26 micromol/L or greater within 48 hours. A 50% or greater rise in serum creatinine known or presumed to have occurred within the past 7 days.\n\nA fall in urine output to less than 0.5 mL/kg/hour for more than 6 hours.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Developing Pulmonary Oedema","description":"Safety Radiology diagnosis or requirement for rescue management (new diuretic use)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Developing Allergy or Anaphylaxis","description":"Requirement for rescue management (antihistamines, adrenaline, intravenous fluids, steroid)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (EQ-5D-5L Questionnaire)","description":"Health Economic Outcomes are measured using the the 5-level EQ-5D version (EQ-5D-5L). The EQ-5D-5L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. A high score indicates a worse outcome. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number (profile) that describes the patient's health state. The EQ-5D profile can be converted to a single number between 0-1 called the EQ-5D value. These EQ-5D values to lie on between 0-1 to indicate health where 0 represents the minimum score (dead) and 1 is full health. Values less than 0 are possible for health states considered worse than dead.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Care Costs","description":"Costs will be estimated by assigning national standard unit costs to inpatient stays (critical care and general ward level), readmissions and additional high costs activities observed in the study. Baseline (pre-admission) HQoL will be estimated using age/sex matched population reference data.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Volume of Randomised Fluid Delivered in Each Arm in the First 24hrs","description":"Secondary Clinical Outcome-Volume of randomised fluid delivered in each arm in the first 24hrs","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1012","spread":"703"},{"groupId":"OG001","value":"2209","spread":"1461"}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (EQ-5D-5L Questionnaire)","description":"Health Economic Outcomes are measured using the the 5-level EQ-5D version (EQ-5D-5L). The EQ-5D-5L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. A high score indicates a worse outcome. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number (profile) that describes the patient's health state. The EQ-5D profile can be converted to a single number between 0-1 called the EQ-5D value. These EQ-5D values to lie on between 0-1 to indicate health where 0 represents the minimum score (dead) and 1 is full health. Values less than 0 are possible for health states considered worse than dead.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (EQ-5D-5L Questionnaire)","description":"Health Economic Outcomes are measured using the the 5-level EQ-5D version (EQ-5D-5L). The EQ-5D-5L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. A high score indicates a worse outcome. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number (profile) that describes the patient's health state. The EQ-5D profile can be converted to a single number between 0-1 called the EQ-5D value. These EQ-5D values to lie on between 0-1 to indicate health where 0 represents the minimum score (dead) and 1 is full health. Values less than 0 are possible for health states considered worse than dead.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":150},"commonTop":["Investigations","Blood and Lymphatic","General disorders and administration","Metabolism and nutrition disorders","Cardiac Disorders"]}}}